Which hedge funds own XERS? XERIS BIOPHARMA HOLDINGS INC, Q2 2026 13F holders
39 tracked hedge funds disclosed a position in XERS (XERIS BIOPHARMA HOLDINGS INC) in their Q2 2026 13F filings, worth $200.4m in total. The largest holder by portfolio weight is Ishara Investments LP at 7.2% of its book. 4 opened a new position this quarter: Perceptive Advisors LLC, Aquatic Capital Management LLC, Walleye Capital LLC, Freestone Grove Partners LP. 9 exited: Voss Capital, LP, Stonepine Capital Management, LLC, Twinbeech Capital LP.
- 39
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 4
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 9
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $10.1m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $12.5m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $200m
- Combined value Sum of the holders' reported positions in the security.
- 3.1%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Voss Capital, LP | 0.5% | $8.0m |
| Stonepine Capital Management, LLC | 0.2% | $232k |
| Twinbeech Capital LP | 0.06% | $564k |
| Scientech Research LLC | 0.05% | $60.4k |
| Engineers Gate Manager LP | 0.01% | $1.1m |
| Mirabella Financial Services LLP | 0.01% | $130k |
| Dark Forest Capital Management LP | 0.01% | $122k |
| Voloridge Investment Management, LLC | 0.01% | $2.1m |
| ExodusPoint Capital Management, LP | 0.0% | $149k |
Ownership over time
Who discovered XERS first? Beta
The run: Q3 2024 → Q3 2026, +235%
| Parkman Healthcare Partners LLC | Q1 2025 | 0.04% | +0.8 pts |
| MPM Bioimpact LLC | Q2 2023 | 1.7% | −0.2 pts |
| Stonepine Capital Management, LLC high conviction | Q4 2021 | – | −1.9 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.